Background: Elevated troponin at baseline is associated with higher mortality in heart failure (HF) patients, but the prognostic role of recurrently elevated troponin is not well described. Methods and results: We performed chart reviews of 196 HF patients without acute coronary syndrome, with at least three Troponin I (TnI) measurements on different admissions. For the analyses, three sets of TnI values closest to baseline, one year and two years were selected for each patient. Based on the three sets of TnI, the lowest value of TnI (minimum), the highest value of TnI (maximum), median value of TnI and delta TnI (3rd TnI-baseline TnI) were derived for each patient. The study population of 196 patients had 632 person-year follow-up, consisted predominantly of elderly (68 ± 10 years) male patients (99%) with mean ejection fraction of 26 ± 13%. Using multivariate Cox proportional hazards model only minimum TnI, but not the maximum, median or delta of TnI values, was significantly associated with mortality (HR: 13.7, 95% CI: 3.7 to 50.8, p < 0.001). As a categorical variable, minimum TnI value of > 0.04 ng/ml was also independently associated with mortality (p = 0.01, HR = 1.6, 95% CI: 1.1 to 2.3). Conclusions: In HF patients without acute coronary syndrome, the persistence of TnI elevation, even at low levels, is associated with a worse survival than sporadic TnI elevations of higher magnitude or any single elevation in TnI; and a recurrent elevation of TnI > 0.04 ng/ml portends a poor prognosis.
|Number of pages||5|
|Journal||International Journal of Cardiology|
|State||Published - Jun 20 2013|
Bibliographical noteFunding Information:
B.B. is supported by NIH 3U01DE017793-S1 and 9K30RR02229. S.A. is supported by fellowship from Alkek Foundation and the American Heart Association.
- Biological markers
- Heart failure
- Retrospective studies
- Survival analysis
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine